PCSK9-IN-10

PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia[1].

Product Specifications

CAS Number

[368434-98-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

PCSK9

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pcsk9-in-10.html

Purity

98.89

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N1C)N(C)C2=C(N(CC3=CC=CC(OC)=C3)C(NCCOC)=N2)C1=O

Molecular Formula

C18H23N5O4

Molecular Weight

373.41

Precautions

H302, H315, H319

References & Citations

[1]Qiao MQ, et al. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis. Eur J Med Chem. 2022 Dec 26;247:115047.